[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Grace Therapeutics Inc (GRCE)

Grace Therapeutics Inc (GRCE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,454
  • Shares Outstanding, K 16,274
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,790 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56

Options Overview Details

View History
  • Implied Volatility 88.23% (+3.66%)
  • Historical Volatility 55.48%
  • IV Percentile 13%
  • IV Rank 4.87%
  • IV High 769.94% on 03/11/26
  • IV Low 53.34% on 01/26/26
  • Expected Move (DTE 15) 0.00 (0.00%)
  • Put/Call Vol Ratio 3.00
  • Today's Volume 8
  • Volume Avg (30-Day) 107
  • Put/Call OI Ratio 0.04
  • Today's Open Interest 4,806
  • Open Int (30-Day) 5,321
  • Expected Range 2.24 to 2.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +475,814.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.08 +7.79%
on 06/29/26
2.69 -16.73%
on 06/02/26
-0.45 (-16.73%)
since 06/01/26
3-Month
1.79 +25.14%
on 04/23/26
5.18 -56.76%
on 04/02/26
-2.64 (-54.10%)
since 04/01/26
52-Week
1.79 +25.14%
on 04/23/26
5.18 -56.76%
on 04/02/26
-0.72 (-24.32%)
since 07/01/25

Most Recent Stories

More News
Quarterly GDP Featured in U.S. Next Week

Monday U.S. Featured Earnings Grace Therapeutics, Inc (NASDAQ: GRCE) (Q4) EPS for loss ...

AYI : 367.53 (-2.42%)
AVAV : 172.44 (+4.46%)
MKC : 52.91 (+4.94%)
PAYX : 102.71 (+4.45%)
MU : 1,032.28 (-10.57%)
APOG : 43.84 (-4.15%)
TCOM : 41.08 (+3.11%)
DRI : 201.95 (-1.97%)
FDX : 313.89 (+0.24%)
GRCE : 2.24 (-1.32%)
CCL : 28.52 (-0.18%)
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined...

GRCE : 2.24 (-1.32%)
Grace: Fiscal Q4 Earnings Snapshot

Grace: Fiscal Q4 Earnings Snapshot

GRCE : 2.24 (-1.32%)
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 11, 2026 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics,...

GRCE : 2.24 (-1.32%)
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES , June 8, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics,...

GRCE : 2.24 (-1.32%)
GRCE Investors Have Opportunity to Join Grace Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grace Therapeutics, Inc. (“Grace” or “the Company”)...

GRCE : 2.24 (-1.32%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

NEW YORK , May 21, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised...

GRCE : 2.24 (-1.32%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE

NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. ("Grace" or the "Company") (NASDAQ: GRCE). Such investors are advised...

GRCE : 2.24 (-1.32%)
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information  FDA Does not Request Additional Clinical Data Company...

GRCE : 2.24 (-1.32%)
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026

PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel,...

GRCE : 2.24 (-1.32%)

Business Summary

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton,...

See More

Key Turning Points

3rd Resistance Point 2.43
2nd Resistance Point 2.39
1st Resistance Point 2.31
Last Price 2.24
1st Support Level 2.19
2nd Support Level 2.15
3rd Support Level 2.07

See More

52-Week High 5.18
Fibonacci 61.8% 3.89
Fibonacci 50% 3.48
Fibonacci 38.2% 3.08
Last Price 2.24
52-Week Low 1.79

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.